
Ocugen Inc OCGN.O:
OCUGEN, INC. ANNOUNCES SIGNING OF BINDING TERM SHEET FOR THE LICENSE OF OCU400 MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA IN KOREA
OCUGEN INC - TO RECEIVE UP TO $11 MILLION IN UPFRONT FEES
OCUGEN INC - SALES MILESTONES OF $150 MILLION OR MORE IN FIRST 10 YEARS OF COMMERCIALIZATION